3207 articles in this topic
A new Cas12a2-based system identifies cancerous or virus-infected cells by their RNA and destroys them — tested across multiple human cancer lines.
JCR Pharmaceuticals shows its JUST-AAV platform can cross the blood-brain barrier, extending survival in neurological disease mouse models.
Insilico Medicine's AI-generated TNIK inhibitor enters Phase 1 trials for pulmonary fibrosis, signaling a new era in drug discovery.
AstraZeneca's BAXFENDY cuts systolic blood pressure by nearly 10 mmHg beyond placebo in adults whose BP wasn't controlled by other drugs.
A Phase 1b trial shows a daily probiotic capsule may restore immunotherapy response in advanced melanoma patients who had stopped responding.
A 20,000-person study finds IgG glycan patterns track biological aging, predict mortality, and shift toward youth with interventions.
A new GLP-1 therapy engineered to cross the blood-brain barrier enters Phase II trials, targeting cognitive decline in Parkinson's and Alzheimer's.
Ossium Health is banking donor bone marrow for on-demand transplant, targeting immune aging as a future healthspan intervention.
Matter Bio files first IND for Listeria-based therapy targeting pancreatic cancer, merging oncology and longevity science.
A comprehensive review of pathophysiology, genetics, and emerging therapies for mitochondrial myopathies, spotlighting elamipretide and gene therapy.
A phase 2b trial finds allogeneic MSC infusions improved 6-minute walk distance by 63 meters vs placebo at 9 months in frail older adults.
A unified mathematical model shows stem cell division rates — not methylation errors — explain why longer-lived species age more slowly.
